Clinical trial participation predicts improved survival in older adults receiving allogeneic blood and marrow transplant.
Allogenic stem cell transplant
Clinical studies
Geriatric
Health equity
Older adults
Oncology
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
04 03 2023
04 03 2023
Historique:
received:
14
09
2022
accepted:
06
02
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Older adults represent a large oncologic demographic and are under-represented within oncology research despite constituting nearly two-thirds of the oncologic population in the United States. Because many social factors influence research participation, those who enroll in research do not reflect the oncology population at large, introducing bias and creating issue with external validity of studies. The same factors that influence study enrollment may also impact cancer outcomes, meaning that those who enroll in studies may already have an improved chance of cancer survival, further skewing results of these studies. This study evaluates characteristics that influence study enrollment in older adults and explore to what degree these factors may influence survival after allogeneic blood or marrow transplantation. This retrospective comparison study evaluates 63 adults aged 60 and above undergoing allogenic transplantation at one institution. Patients who elected and declined enrollment in a non-therapeutic observational study were evaluated. Demographic and clinical characteristics between groups were compared and assessed as predictors of transplant survival, including decision to enroll in the study. Participants who chose to enroll in the parent study were not different with regard to gender, race/ethnicity, age, insurance type, donor age, and neighborhood income/poverty level compared to patients who were invited to participate but declined enrollment. The research participant group had higher proportion assessed as being fully active (23.8% vs. 12.7%, p = 0.034) and lower mean comorbidity scores (1.0 vs 2.47, p = 0.008). Enrollment in an observational study independently predicted transplant survival (HR = 0.316, 95% CI 0.12-0.82, p = 0.017). When controlling for relevant confounders of disease severity, comorbidities, and transplant age, enrolling in the parent study was associated with a lower hazards of death following transplant (HR = 0.302, 95% CI 0.10-0.87, p = 0.027). Despite being demographically comparable, persons who enrolled in one non-therapeutic transplant study had significantly improved survivorship than those who did not participate in observational research. These findings suggest that there are unidentified factors that influence study involvement that may also impact disease survivorship, over-estimating outcomes from these studies. Results from prospective observational studies should be interpreted with the consideration that study participants have an improved chance of survival at baseline.
Sections du résumé
BACKGROUND
Older adults represent a large oncologic demographic and are under-represented within oncology research despite constituting nearly two-thirds of the oncologic population in the United States. Because many social factors influence research participation, those who enroll in research do not reflect the oncology population at large, introducing bias and creating issue with external validity of studies. The same factors that influence study enrollment may also impact cancer outcomes, meaning that those who enroll in studies may already have an improved chance of cancer survival, further skewing results of these studies. This study evaluates characteristics that influence study enrollment in older adults and explore to what degree these factors may influence survival after allogeneic blood or marrow transplantation.
METHODS
This retrospective comparison study evaluates 63 adults aged 60 and above undergoing allogenic transplantation at one institution. Patients who elected and declined enrollment in a non-therapeutic observational study were evaluated. Demographic and clinical characteristics between groups were compared and assessed as predictors of transplant survival, including decision to enroll in the study.
RESULTS
Participants who chose to enroll in the parent study were not different with regard to gender, race/ethnicity, age, insurance type, donor age, and neighborhood income/poverty level compared to patients who were invited to participate but declined enrollment. The research participant group had higher proportion assessed as being fully active (23.8% vs. 12.7%, p = 0.034) and lower mean comorbidity scores (1.0 vs 2.47, p = 0.008). Enrollment in an observational study independently predicted transplant survival (HR = 0.316, 95% CI 0.12-0.82, p = 0.017). When controlling for relevant confounders of disease severity, comorbidities, and transplant age, enrolling in the parent study was associated with a lower hazards of death following transplant (HR = 0.302, 95% CI 0.10-0.87, p = 0.027).
CONCLUSIONS
Despite being demographically comparable, persons who enrolled in one non-therapeutic transplant study had significantly improved survivorship than those who did not participate in observational research. These findings suggest that there are unidentified factors that influence study involvement that may also impact disease survivorship, over-estimating outcomes from these studies. Results from prospective observational studies should be interpreted with the consideration that study participants have an improved chance of survival at baseline.
Identifiants
pubmed: 36869287
doi: 10.1186/s12877-023-03803-7
pii: 10.1186/s12877-023-03803-7
pmc: PMC9985233
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120Informations de copyright
© 2023. The Author(s).
Références
Eur J Cancer. 1996 Jun;32A(7):1135-41
pubmed: 8758243
Support Care Cancer. 2019 Oct;27(10):3793-3798
pubmed: 30721369
Blood. 2017 Aug 31;130(9):1156-1164
pubmed: 28674027
Blood. 2013 Apr 11;121(15):2854-63
pubmed: 23355537
Br J Cancer. 2021 Jan;124(2):315-332
pubmed: 32901135
JCO Oncol Pract. 2021 May;17(5):e666-e675
pubmed: 33974821
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Clin Oncol. 2017 Apr 10;35(11):1154-1161
pubmed: 28380315
Transpl Int. 2017 Jan;30(1):6-10
pubmed: 27896874
Biol Blood Marrow Transplant. 2019 Oct;25(10):2086-2090
pubmed: 31228584
Eur J Cardiothorac Surg. 2019 Feb 1;55(2):179-185
pubmed: 30596979
Blood. 2012 Jul 26;120(4):905-13
pubmed: 22709687
Control Clin Trials. 1995 Oct;16(5):277-85; discussion 286-9, 293-309
pubmed: 8582146
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282